0RAD Stock Chart & Stats
€3.19
-€0.53(-6.99%)
At close: 4:00 PM EST
€3.19
-€0.53(-6.99%)
Day’s Range― - ―
52-Week Range€2.95 - €7.64
Previous CloseN/A
Volume90.00
Average Volume (3M)808.00
Market Cap
€79.10M
Enterprise Value€102.63M
Total Cash (Recent Filing)€22.65M
Total Debt (Recent Filing)€35.38M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume1,092
30 Day Avg. Volume808
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)€6.17M
Bulls Say, Bears Say
Bulls Say
Pipeline & Collaboration ModelOSE's business model centers on an R&D pipeline plus external collaborations and licensing. Structurally, this reduces capital intensity versus direct commercialization, enables milestone/royalty revenue potential, and leverages partner resources to advance programs over months to years.
Demonstrated Milestone Cash GenerationThe company has shown it can generate large episodic cash inflows (2024 operating/FCF ~48.4M), indicating the firm can secure partnership payments or milestones. This structural ability to episodically self-fund development reduces perpetual reliance on capital markets when events occur.
Tangible Asset BaseA reported asset base (~78.4M) provides tangible resources and some collateral headroom to support R&D and licensing negotiations. While equity has been eroded, these assets give the company runway and bargaining power with partners or lenders during multi-month development cycles.
Bears Say
Revenue & Earnings VolatilityRevenue and earnings swing dramatically year-to-year, largely driven by timing of one-off payments. Such structural volatility undermines forecasting, makes operational planning difficult, and weakens credit/funding terms because recurring revenue streams are absent until commercial products exist.
Recent Shift To Material Cash BurnA shift from strong positive cash flow to sizeable negative operating and free cash flow increases structural funding risk. Sustained burn forces reliance on equity issuance, debt, or partner financing, raising dilution or covenant pressure over the medium term unless new milestone receipts occur.
Debt Exceeds EquityMeaningful leverage with debt above equity reduces financial flexibility and raises refinancing risk. With losses eroding the capital base, high indebtedness increases the chance of restrictive covenants, higher financing costs, or constrained program spending absent partner funding or capital raises.
OSE Immunotherapeutics SA News
0RAD FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest share price was €2.95 and its highest was €7.64 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €79.10M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Sep 28, 2026 which is in 43 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€1.007.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.008%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in GB:0RAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.